51
|
Tillisch K, Labus JS. Neuroimaging the microbiome-gut-brain axis. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 817:405-16. [PMID: 24997044 DOI: 10.1007/978-1-4939-0897-4_18] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The brain is the most complex organ in the human body, interacting with every other major organ system to continuously maintain homeostasis. Thus it is not surprising that the brain also interacts with our microbiota, the trillions of bacteria and other organisms inhabiting the ecosystem of the human being. As we gather knowledge about the way that our microbiota interact with their local environments, there is also increasing interest in their communication with the brain.
Collapse
Affiliation(s)
- Kirsten Tillisch
- Division of Digestive Diseases, Department of Medicine, Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, CHS 42-210 MC737818, 957378, Los Angeles, CA, 90095-7378, USA,
| | | |
Collapse
|
52
|
Abstract
PURPOSE OF REVIEW The current review gives an overview about recent advances in neuroimaging studies with specific emphasis on pharmacological modulation of pain and headache. Further, we want to highlight how imaging methods have changed our understanding of chronic pain and discuss how pharmacological MRI could lead to new insights into underlying mechanisms of headache and pain. RECENT FINDINGS Several studies from different imaging laboratories have highlighted the outstanding role of imaging in getting a deeper insight regarding the central mechanisms of drugs. Neuroimaging techniques start to unravel how analgesic drugs, antidepressants or NSAIDs act on pain perception and in particular on central pain processes. Furthermore, the studies included in this review show how context dependent drugs act and how differently they reveal their action in the human brain. SUMMARY Imaging techniques give us the opportunity to gain a better understanding of drug processes in the central nervous system and help to understand where drugs reveal their therapeutic effect. While some substances work on the emotional-affective component of pain, others modulate sensory-discriminative pain pathways. Especially in the field of headache research, still a lot has to be done to understand how preventatives and acute medication modulate the human brain. Future studies should also replicate and extend recent findings.
Collapse
|
53
|
Arendt-Nielsen L, Curatolo M. Mechanistic, translational, quantitative pain assessment tools in profiling of pain patients and for development of new analgesic compounds. Scand J Pain 2013; 4:226-230. [DOI: 10.1016/j.sjpain.2013.07.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 07/22/2013] [Indexed: 01/05/2023]
Abstract
Abstract
Background
Mechanistic, translational, human experimental pain assessment technologies (pain bio markers) can be used for: (1) profiling the responsiveness of various pain mechanisms and pathways in healthy volunteers and pain patients, and (2) profiling the effect of new or existing analgesic drugs or pain management procedures. Translational models, which may link mechanisms in animals to humans, are important to understand pain mechanisms involved in pain patients and as tools for drug development. This is urgently needed as many drugs which are effective in animal models fail to be efficient in patients as neither the mechanisms involved in patients nor the drugs’ mechanistic actions are known.
Aim
The aim of the present topical review is to provide the basis for how to use mechanistic human experimental pain assessment tools (pain bio markers) in the development of new analgesics and to characterise and diagnose pain patients. The future aim will be to develop such approaches into individualised pain management regimes.
Method
Experimental pain bio markers can tease out mechanistically which pain pathways and mechanisms are modulated in a given patient, and how a given compound modulates them. In addition, pain bio markers may be used to assess pain from different structures (skin, muscle and viscera) and provoke semi-pathophysiological conditions (e.g. hyperalgesia, allodynia and after-sensation) in healthy volunteers using surrogate pain models.
Results
With this multi-modal, multi-tissue, multi-mechanism pain assessment regime approach, new opportunities have emerged for profiling pain patients and optimising drug development. In this context these technologies may help to validate targets (proof-of-concept), provide dose-response relationships, predicting which patient population/characteristics will respond to a given treatment (individualised pain management), and hence provide better understanding of the underlying cause for responders versus non-responders to a given treatment.
Conclusion
In recent years, pain bio markers have been substantially developed to have now a role to play in early drug development, providing valuable mechanistic understanding of the drug action and used to characterise/profile pain patients. In drug development phase I safety volunteer studies, pain bio marker scan provide indication of efficacy and later if feasible be included in clinical phase II, III, and IV studies to substantiate mode-of-action.
Implications
Refining and optimizing the drug development process ensures a higher success rate, i.e. not discarding drugs that may be efficient and not push non-efficient drugs too far in the costly development process. Mechanism-based pain bio markers can help to qualify the development programmes and at the same time help qualifying them by pain profiling (phenotyping) and recognising the right patients for specific trials. The success rate from preclinical data to clinical outcome may be further facilitated by using specific translational pain bio-markers. As human pain bio markers are getting more and more advanced it could be expected that FDA and EMA in the future will pay more attention to such mechanism-related measures in the approval phase as proof-of-action.
Collapse
Affiliation(s)
- Lars Arendt-Nielsen
- Center for Sensory-Motor lnteraction (SMI), Department of Health Science and Technology, Faculty of Medicine , Aalborg University , Aalborg , Denmark
| | - Michele Curatolo
- Department of Anaesthesiology and Pain Medicine , University of Washington , Seattle , WA , USA
| |
Collapse
|
54
|
Rodriguez-Rojas R, Machado C, Alvarez L, Carballo M, Estevez M, Perez-Nellar J, Pavon N, Chinchilla M, Carrick FR, DeFina P. Zolpidem induces paradoxical metabolic and vascular changes in a patient with PVS. Brain Inj 2013; 27:1320-9. [PMID: 23924270 DOI: 10.3109/02699052.2013.794961] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
INTRODUCTION Zolpidem is a non-benzodiazepine drug used for the therapy of insomnia, which has selectivity for stimulating the effect of GABA-A receptors. Recently, a paradoxical arousing effect of zolpidem in patients with severe brain damage has been repeatedly reported. METHODS A placebo-controlled magnetic resonance study was conducted to evaluate its effect on BOLD and metabolites spectral signals in a patient with severe brain injuries and an age-matched healthy volunteer. A multi-modal analysis was used to assess aspects in the pharmacologically-induced changes in the resting-state brain metabolism. RESULTS A significantly increased BOLD signal was transiently localized in the left frontal cortices, bilateral anterior cingulated areas, left thalamus and right head of the caudate nucleus. The healthy subject showed a deactivation of the frontal, parietal and temporal cortices. BOLD signal changes were found to significantly correlate with concentrations of extravascular metabolites in the left frontal cortex. It is discussed that, when zolpidem attaches to modified GABA receptors of neurodormant brain cells, brain activation is induced. This might explain the significant correlations of BOLD signal changes and proton-MRS metabolites in this patient after zolpidem. CONCLUSION It was concluded that proton-MRS and BOLD signal assessment could be used to study zolpidem-induced metabolic modulation in a resting state.
Collapse
|
55
|
Antinociceptive activity of crotoxin in the central nervous system: a functional Magnetic Resonance Imaging study. Toxicon 2013; 74:44-55. [PMID: 23916599 DOI: 10.1016/j.toxicon.2013.07.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Revised: 07/19/2013] [Accepted: 07/25/2013] [Indexed: 11/23/2022]
Abstract
Crotoxin, the main neurotoxic component of the venom of South American rattlesnake (Crotalus durissus terrificus), is reported to have potent antinociceptive activity. Several authors have shown mainly in behavioral pain models that crotoxin induces antinociceptive effects, supposed to be mediated by actions on the central nervous system. The antinociceptive effects of crotoxin (45 μg/kg ip) in rats were verified in this study by increased response latencies in a Hargreaves test and tail flick test. In addition, it was demonstrated that crotoxin does not lead to motor impairments during a rotarod test and open field test. The main objective, carried out by blood oxygen level dependent functional Magnetic Resonance Imaging (BOLD fMRI) in anesthetized rats, was to determine which specific brain structures are involved in these antinociceptive effects. Moreover, potential antihyperalgesic effects were investigated by inducing a local hyperalgesia on the left hind paw. Therefore, antinociceptive effects (right paw) and antihyperalgesic effects (left paw) of crotoxin were able to be differentiated. As a result, crotoxin exhibited dominant antihyperalgesic but also antinociceptive effects during pain stimulation. Reductions of BOLD signal already occurred in brain input structures but were most prominent in primary and secondary somatosensory cortices. In conclusion, BOLD fMRI in anesthetized rats proved to be a helpful tool in toxinology, particularly in unraveled mechanisms of modulating nociception in the central nervous system by (potential) analgesics like crotoxin.
Collapse
|
56
|
Broberg BV, Madsen KH, Plath N, Olsen CK, Glenthøj BY, Paulson OB, Bjelke B, Søgaard LV. A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging. Behav Brain Res 2013; 250:1-8. [DOI: 10.1016/j.bbr.2013.04.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 04/18/2013] [Accepted: 04/20/2013] [Indexed: 12/15/2022]
|
57
|
Lee MC, Wanigasekera V, Tracey I. Imaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain. Neuropharmacology 2013; 84:123-30. [PMID: 23891639 PMCID: PMC4067746 DOI: 10.1016/j.neuropharm.2013.06.035] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/19/2013] [Accepted: 06/27/2013] [Indexed: 01/09/2023]
Abstract
Opioids play an important role for the management of acute pain and in palliative care. The role of long-term opioid therapy in chronic non-malignant pain remains unclear and is the focus of much clinical research. There are concerns regarding analgesic tolerance, paradoxical pain and issues with dependence that can occur with chronic opioid use in the susceptible patient. In this review, we discuss how far human neuroimaging research has come in providing a mechanistic understanding of pain relief provided by opioids, and suggest avenues for further studies that are relevant to the management of chronic pain with opioids. This article is part of the Special Issue Section entitled ‘Neuroimaging in Neuropharmacology’. Brain mechanisms are crucial to opioid analgesia in humans. Opioids can have a direct effect on brain mechanisms for pain perception. Opioids can also engage descending inhibition of spinal nociception. Drug-induced tolerance, dependence and paradoxical pain may limit chronic opioid analgesic therapy.
Collapse
Affiliation(s)
- Michael C Lee
- Centre for Functional MRI of the Brain (FMRIB), Department of Clinical Neurology and Nuffield Department of Clinical Neurosciences, Division of Anaesthesia, United Kingdom.
| | - Vishvarani Wanigasekera
- Centre for Functional MRI of the Brain (FMRIB), Department of Clinical Neurology and Nuffield Department of Clinical Neurosciences, Division of Anaesthesia, United Kingdom
| | - Irene Tracey
- Centre for Functional MRI of the Brain (FMRIB), Department of Clinical Neurology and Nuffield Department of Clinical Neurosciences, Division of Anaesthesia, United Kingdom.
| |
Collapse
|
58
|
Minzenberg MJ, Carter CS. The quest for developing new treatments from imaging techniques: promises, problems and future potential. Expert Opin Drug Discov 2013; 2:1029-33. [PMID: 23484869 DOI: 10.1517/17460441.2.8.1029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Drug discovery and development in psychiatry is beset by many challenges, both those which are associated with the development process in general (and affecting all of medicine) and others, which are unique to psychiatry. Due to these factors, marginal progress has been achieved in the past as many features of serious mental illness remain untouched by existing treatments. Arguably, the most important of these drug targets is cognitive dysfunction, which strongly predicts clinical outcome in a number of major neuropsychiatric conditions. Therefore, a critical need exists for progress in the characterization of this and other targets for drug discovery and development. A key area, which is already showing promise, is the use of non-invasive functional neuroimaging to investigate both cognitive dysfunction and its remediation with novel agents. In this article, the authors describe the paradigmatic case of cognitive dysfunction in schizophrenia, and the prospects for using functional magnetic resonance imaging (fMRI) to investigate the effects of agents targeting cognition. The authors observe a number of advantages of this approach over other methodologies, as well as some significant issues to be resolved in the application of this technology. The authors propose that pharmaco-fMRI is emerging as a major tool to enhance the drug development process in order to bring truly novel treatments to patients with a range of neuropsychiatric disorders.
Collapse
Affiliation(s)
- Michael J Minzenberg
- University of California, Imaging Research Center, Davis School of Medicine, 4701 X Street, Sacramento, CA 95817, USA +1 916 734 7174 ; +1 916 734 7850 ;
| | | |
Collapse
|
59
|
Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013; 154:124-134. [PMID: 23273106 PMCID: PMC3549497 DOI: 10.1016/j.pain.2012.09.017] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 09/15/2012] [Accepted: 09/29/2012] [Indexed: 01/20/2023]
Abstract
Cannabis is reported to be remarkably effective for the relief of otherwise intractable pain. However, the bases for pain relief afforded by this psychotropic agent are debatable. Nonetheless, the frontal-limbic distribution of cannabinoid receptors in the brain suggests that cannabis may target preferentially the affective qualities of pain. This central mechanism of action may be relevant to cannabinoid analgesia in humans, but has yet to be demonstrated. Here, we employed functional magnetic resonance imaging to investigate the effects of delta-9-tetrahydrocannabinol (THC), a naturally occurring cannabinoid, on brain activity related to cutaneous ongoing pain and hyperalgesia that were temporarily induced by capsaicin in healthy volunteers. On average, THC reduced the reported unpleasantness, but not the intensity of ongoing pain and hyperalgesia: the specific analgesic effect on hyperalgesia was substantiated by diminished activity in the anterior mid cingulate cortex. In individuals, the drug-induced reduction in the unpleasantness of hyperalgesia was positively correlated with right amygdala activity. THC also reduced functional connectivity between the amygdala and primary sensorimotor areas during the ongoing-pain state. Critically, the reduction in sensory-limbic functional connectivity was positively correlated with the difference in drug effects on the unpleasantness and the intensity of ongoing pain. Peripheral mechanisms alone cannot account for the dissociative effects of THC on the pain that was observed. Instead, the data reveal that amygdala activity contributes to interindividual response to cannabinoid analgesia, and suggest that dissociative effects of THC in the brain are relevant to pain relief in humans.
Collapse
|
60
|
Brain imaging reveals that engagement of descending inhibitory pain pathways in healthy women in a low endogenous estradiol state varies with testosterone. Pain 2013; 154:515-524. [DOI: 10.1016/j.pain.2012.11.016] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Revised: 09/12/2012] [Accepted: 11/30/2012] [Indexed: 11/23/2022]
|
61
|
Caballero Gaudes C, Petridou N, Francis ST, Dryden IL, Gowland PA. Paradigm free mapping with sparse regression automatically detects single-trial functional magnetic resonance imaging blood oxygenation level dependent responses. Hum Brain Mapp 2013; 34:501-18. [PMID: 22121048 PMCID: PMC6870268 DOI: 10.1002/hbm.21452] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2011] [Revised: 07/13/2011] [Accepted: 08/04/2011] [Indexed: 11/08/2022] Open
Abstract
The ability to detect single trial responses in functional magnetic resonance imaging (fMRI) studies is essential, particularly if investigating learning or adaptation processes or unpredictable events. We recently introduced paradigm free mapping (PFM), an analysis method that detects single trial blood oxygenation level dependent (BOLD) responses without specifying prior information on the timing of the events. PFM is based on the deconvolution of the fMRI signal using a linear hemodynamic convolution model. Our previous PFM method (Caballero-Gaudes et al., 2011: Hum Brain Mapp) used the ridge regression estimator for signal deconvolution and required a baseline signal period for statistical inference. In this work, we investigate the application of sparse regression techniques in PFM. In particular, a novel PFM approach is developed using the Dantzig selector estimator, solved via an efficient homotopy procedure, along with statistical model selection criteria. Simulation results demonstrated that, using the Bayesian information criterion to select the regularization parameter, this method obtains high detection rates of the BOLD responses, comparable with a model-based analysis, but requiring no information on the timing of the events and being robust against hemodynamic response function variability. The practical operation of this sparse PFM method was assessed with single-trial fMRI data acquired at 7T, where it automatically detected all task-related events, and was an improvement on our previous PFM method, as it does not require the definition of a baseline state and amplitude thresholding and does not compromise on specificity and sensitivity.
Collapse
Affiliation(s)
- César Caballero Gaudes
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom.
| | | | | | | | | |
Collapse
|
62
|
Khalili-Mahani N, van Osch MJ, de Rooij M, Beckmann CF, van Buchem MA, Dahan A, van Gerven JM, Rombouts SARB. Spatial heterogeneity of the relation between resting-state connectivity and blood flow: an important consideration for pharmacological studies. Hum Brain Mapp 2012; 35:929-42. [PMID: 23281174 DOI: 10.1002/hbm.22224] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 10/08/2012] [Accepted: 10/22/2012] [Indexed: 01/28/2023] Open
Abstract
Resting state fMRI (RSfMRI) and arterial spin labeling (ASL) provide the field of pharmacological Neuroimaging tool for investigating states of brain activity in terms of functional connectivity or cerebral blood flow (CBF). Functional connectivity reflects the degree of synchrony or correlation of spontaneous fluctuations--mostly in the blood oxygen level dependent (BOLD) signal--across brain networks; but CBF reflects mean delivery of arterial blood to the brain tissue over time. The BOLD and CBF signals are linked to common neurovascular and hemodynamic mechanisms that necessitate increased oxygen transportation to the site of neuronal activation; however, the scale and the sources of variation in static CBF and spatiotemporal BOLD correlations are likely different. We tested this hypothesis by examining the relation between CBF and resting-state-network consistency (RSNC)--representing average intranetwork connectivity, determined from dual regression analysis with eight standard networks of interest (NOIs)--in a crossover placebo-controlled study of morphine and alcohol. Overall, we observed spatially heterogeneous relations between RSNC and CBF, and between the experimental factors (drug-by-time, time, drug and physiological rates) and each of these metrics. The drug-by-time effects on CBF were significant in all networks, but significant RSNC changes were limited to the sensorimotor, the executive/salience and the working memory networks. The post-hoc voxel-wise statistics revealed similar dissociations, perhaps suggesting differential sensitivity of RSNC and CBF to neuronal and vascular endpoints of drug actions. The spatial heterogeneity of RSNC/CBF relations encourages further investigation into the role of neuroreceptor distribution and cerebrovascular anatomy in predicting spontaneous fluctuations under drugs.
Collapse
Affiliation(s)
- Najmeh Khalili-Mahani
- Institute of Psychology, Leiden University, Leiden, The Netherlands; Department of Radiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; Leiden Institute for Brain and Cognition (LIBC), Leiden University, Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
63
|
Plichta MM, Schwarz AJ, Grimm O, Morgen K, Mier D, Haddad L, Gerdes ABM, Sauer C, Tost H, Esslinger C, Colman P, Wilson F, Kirsch P, Meyer-Lindenberg A. Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery. Neuroimage 2012; 60:1746-58. [PMID: 22330316 DOI: 10.1016/j.neuroimage.2012.01.129] [Citation(s) in RCA: 222] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Revised: 01/26/2012] [Accepted: 01/28/2012] [Indexed: 11/26/2022] Open
Abstract
Even more than in cognitive research applications, moving fMRI to the clinic and the drug development process requires the generation of stable and reliable signal changes. The performance characteristics of the fMRI paradigm constrain experimental power and may require different study designs (e.g., crossover vs. parallel groups), yet fMRI reliability characteristics can be strongly dependent on the nature of the fMRI task. The present study investigated both within-subject and group-level reliability of a combined three-task fMRI battery targeting three systems of wide applicability in clinical and cognitive neuroscience: an emotional (face matching), a motivational (monetary reward anticipation) and a cognitive (n-back working memory) task. A group of 25 young, healthy volunteers were scanned twice on a 3T MRI scanner with a mean test-retest interval of 14.6 days. FMRI reliability was quantified using the intraclass correlation coefficient (ICC) applied at three different levels ranging from a global to a localized and fine spatial scale: (1) reliability of group-level activation maps over the whole brain and within targeted regions of interest (ROIs); (2) within-subject reliability of ROI-mean amplitudes and (3) within-subject reliability of individual voxels in the target ROIs. Results showed robust evoked activation of all three tasks in their respective target regions (emotional task=amygdala; motivational task=ventral striatum; cognitive task=right dorsolateral prefrontal cortex and parietal cortices) with high effect sizes (ES) of ROI-mean summary values (ES=1.11-1.44 for the faces task, 0.96-1.43 for the reward task, 0.83-2.58 for the n-back task). Reliability of group level activation was excellent for all three tasks with ICCs of 0.89-0.98 at the whole brain level and 0.66-0.97 within target ROIs. Within-subject reliability of ROI-mean amplitudes across sessions was fair to good for the reward task (ICCs=0.56-0.62) and, dependent on the particular ROI, also fair-to-good for the n-back task (ICCs=0.44-0.57) but lower for the faces task (ICC=-0.02-0.16). In conclusion, all three tasks are well suited to between-subject designs, including imaging genetics. When specific recommendations are followed, the n-back and reward task are also suited for within-subject designs, including pharmaco-fMRI. The present study provides task-specific fMRI reliability performance measures that will inform the optimal use, powering and design of fMRI studies using comparable tasks.
Collapse
Affiliation(s)
- Michael M Plichta
- Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
64
|
Abstract
Neuroimaging allows researchers and clinicians to noninvasively assess structure and function of the brain. With the advances of imaging modalities such as magnetic resonance, nuclear, and optical imaging; the design of target-specific probes; and/or the introduction of reporter gene assays, these technologies are now capable of visualizing cellular and molecular processes in vivo. Undoubtedly, the system biological character of molecular neuroimaging, which allows for the study of molecular events in the intact organism, will enhance our understanding of physiology and pathophysiology of the brain and improve our ability to diagnose and treat diseases more specifically. Technical/scientific challenges to be faced are the development of highly sensitive imaging modalities, the design of specific imaging probe molecules capable of penetrating the CNS and reporting on endogenous cellular and molecular processes, and the development of tools for extracting quantitative, biologically relevant information from imaging data. Today, molecular neuroimaging is still an experimental approach with limited clinical impact; this is expected to change within the next decade. This article provides an overview of molecular neuroimaging approaches with a focus on rodent studies documenting the exploratory state of the field. Concepts are illustrated by discussing applications related to the pathophysiology of Alzheimer's disease.
Collapse
Affiliation(s)
- Jan Klohs
- Institute for Biomedical Engineering, ETH & University of Zürich, Switzerland
| | | |
Collapse
|
65
|
Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke. Transl Stroke Res 2012; 3:36-43. [PMID: 22408692 PMCID: PMC3284658 DOI: 10.1007/s12975-011-0143-8] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 12/23/2011] [Accepted: 12/27/2011] [Indexed: 11/27/2022]
Abstract
The potential of the adult brain to reorganize after ischemic injury is critical for functional recovery and provides a significant target for therapeutic strategies to promote brain repair. Despite the accumulating evidence of brain plasticity, the interaction and significance of morphological and physiological modifications in post-stroke brain tissue remain mostly unclear. Neuroimaging techniques such as functional MRI (fMRI) and diffusion tensor imaging (DTI) enable in vivo assessment of the spatial and temporal pattern of functional and structural changes inside and outside ischemic lesion areas. This can contribute to the elucidation of critical aspects in post-stroke brain remodeling. Task/stimulus-related fMRI, resting-state fMRI, or pharmacological MRI enables direct or indirect measurement of neuronal activation, functional connectivity, or neurotransmitter system responses, respectively. DTI allows estimation of the structural integrity and connectivity of white matter tracts. Together, these MRI methods provide an unprecedented means to (a) measure longitudinal changes in tissue structure and function close by and remote from ischemic lesion areas, (b) evaluate the organizational profile of neural networks after stroke, and (c) identify degenerative and restorative processes that affect post-stroke functional outcome. Besides, the availability of MRI in clinical institutions as well as research laboratories provides an optimal basis for translational research on stroke recovery. This review gives an overview of the current status and perspectives of fMRI and DTI applications to study brain reorganization in experimental stroke models.
Collapse
|
66
|
Liu X, Li R, Yang Z, Hudetz AG, Li SJ. Differential effect of isoflurane, medetomidine, and urethane on BOLD responses to acute levo-tetrahydropalmatine in the rat. Magn Reson Med 2011; 68:552-9. [PMID: 22213080 DOI: 10.1002/mrm.23243] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Revised: 08/02/2011] [Accepted: 09/12/2011] [Indexed: 11/08/2022]
Abstract
Levo-tetrahydropalmatine (l-THP) has shown significant promise in preclinical and clinical studies to treat drug addiction. Pharmacological MRI methods can elucidate the regional cerebral effects of l-THP, but there are potential confounds from the use of general anesthesia. To investigate the possible anesthetic-drug interactions for the pharmacological MRI result of acute l-THP, we examined acute blood oxygen level-dependent responses of both 5 and 20 mg/kg l-THP in naïve rats during general anesthesia achieved with three agents: isoflurane, medetomidine, and urethane. We found that with acute l-THP administration, isoflurane revealed the smallest blood oxygen level-dependent activation areas. In addition, urethane had the most activation areas; however, they were all negative. Medetomidine showed mixed positive and negative activations. Region-specific interactions were found between the l-THP-induced blood oxygen level-dependent responses and the anesthetic agents.
Collapse
Affiliation(s)
- Xiping Liu
- Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | | | | | | | | |
Collapse
|
67
|
Minas G, Rigat F, Nichols TE, Aston JAD, Stallard N. A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies. Stat Med 2011; 31:253-68. [PMID: 22170084 DOI: 10.1002/sim.4395] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Accepted: 08/01/2011] [Indexed: 11/10/2022]
Abstract
In multivariate clinical trials, a key research endpoint is ascertaining whether a candidate treatment is more efficacious than an established alternative. This global endpoint is clearly of high practical value for studies, such as those arising from neuroimaging, where the outcome dimensions are not only numerous but they are also highly correlated and the available sample sizes are typically small. In this paper, we develop a two-stage procedure testing the null hypothesis of global equivalence between treatments effects and demonstrate its application to analysing phase II neuroimaging trials. Prior information such as suitable statistics of historical data or suitably elicited expert clinical opinions are combined with data collected from the first stage of the trial to learn a set of optimal weights. We apply these weights to the outcome dimensions of the second-stage responses to form the linear combination z and t tests statistics while controlling the test's false positive rate. We show that the proposed tests hold desirable asymptotic properties and characterise their power functions under wide conditions. In particular, by comparing the power of the proposed tests with that of Hotelling's T(2), we demonstrate their advantages when sample sizes are close to the dimension of the multivariate outcome. We apply our methods to fMRI studies, where we find that, for sufficiently precise first stage estimates of the treatment effect, standard single-stage testing procedures are outperformed.
Collapse
Affiliation(s)
- Giorgos Minas
- Department of Statistics, University of Warwick, Coventry, UK.
| | | | | | | | | |
Collapse
|
68
|
Wolf DH, Satterthwaite TD, Loughead J, Pinkham A, Overton E, Elliott MA, Dent GW, Smith MA, Gur RC, Gur RE. Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge. Psychopharmacology (Berl) 2011; 218:503-12. [PMID: 21603892 PMCID: PMC3962022 DOI: 10.1007/s00213-011-2348-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2011] [Accepted: 05/02/2011] [Indexed: 12/14/2022]
Abstract
RATIONALE Impaired emotion processing in schizophrenia predicts broader social dysfunction and has been related to negative symptom severity and amygdala dysfunction. Pharmacological modulation of emotion-processing deficits and related neural abnormalities may provide useful phenotypes for pathophysiological investigation. OBJECTIVES We used an acute benzodiazepine challenge to identify and modulate potential emotion-processing abnormalities in 20 unaffected first-degree relatives of individuals with schizophrenia, compared to 25 control subjects without a family history of psychosis. METHODS An oral 1 mg dose of the short-acting anxiolytic benzodiazepine alprazolam was administered in a balanced crossover placebo-controlled double-blind design, preceding identical 3 T fMRI sessions approximately 1 week apart. Primary outcomes included fMRI activity in amygdala and related regions during two facial emotion-processing tasks: emotion identification and emotion memory. RESULTS Family members exhibited abnormally strong alprazolam-induced reduction in amygdala and hippocampus activation during emotion identification, compared to equal reduction in both groups for the emotion memory task. CONCLUSIONS GABAergic modulation with alprazolam produced differential responses in family members vs. controls, perhaps by unmasking underlying amygdalar and/or GABAergic abnormalities. Such pharmacological fMRI paradigms could prove useful for developing drugs targeting specific neural circuits to treat or prevent schizophrenia.
Collapse
Affiliation(s)
- Daniel H Wolf
- Department of Psychiatry, University of Pennsylvania, 10th Floor Gates Bldg., 3400 Spruce St., Philadelphia, PA 19104, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Li X, Large CH, Ricci R, Taylor JJ, Nahas Z, Bohning DE, Morgan P, George MS. Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. Psychiatry Res 2011; 194:141-8. [PMID: 21924874 DOI: 10.1016/j.pscychresns.2011.04.012] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2010] [Revised: 04/27/2011] [Accepted: 04/28/2011] [Indexed: 10/17/2022]
Abstract
The purpose of this study was to use interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (TMS/fMRI) to investigate the effects of lamotrigine (LTG) and valproic acid (VPA) on effective connectivity within motor and corticolimbic circuits. In this randomized, double-blind, crossover trial, 30 healthy volunteers received either drug or placebo 3.5 h prior to interleaved TMS/fMRI. We utilized dynamic causal modeling (DCM) to assess changes in the endogenous effective connectivity of bidirectional networks in the motor-sensory system and corticolimbic circuit. Results indicate that both LTG and VPA have network-specific effects. When TMS was applied over the motor cortex, both LTG and VPA reduced TMS-specific effective connectivity between primary motor (M1) and pre-motor cortex (PMd), and between M1 and the supplementary area motor (SMA). When TMS was applied over prefrontal cortex, however, LTG alone increased TMS-specific effective connectivity between the left dorsolateral prefrontal cortex(DLPFC) and the anterior cingulate cortex (ACC). In summary, LTG and VPA inhibited effective connectivity in motor circuits, but LTG alone increased effective connectivity in prefrontal circuits. These results suggest that interleaved TMS/fMRI can assess region- and circuit-specific effects of medications or interventions.
Collapse
Affiliation(s)
- Xingbao Li
- Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.
| | | | | | | | | | | | | | | |
Collapse
|
70
|
Sekar S, Van Audekerke J, Vanhoutte G, Lowe AS, Blamire AM, Van der Linden A, Steckler T, Shoaib M, Verhoye M. Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2011; 217:549-57. [PMID: 21553005 DOI: 10.1007/s00213-011-2311-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2010] [Accepted: 04/11/2011] [Indexed: 11/29/2022]
Abstract
RATIONALE One of the key targets of psychopharmacology research is to determine the potential sites of action of antidepressants in order to characterise their underlying mechanism of action. OBJECTIVE Using blood oxygenation level-dependent (BOLD) pharmacological magnetic resonance imaging (phMRI), the neuroanatomical target-sites of reboxetine (a selective noradrenaline reuptake inhibitor) and bupropion (an antidepressant with stimulatory effects on dopamine and potentially on noradrenaline) were mapped. METHODS Separate groups of rats were challenged acutely or chronically (daily injections for 14 days) with saline or psychoactive compounds and scanned. Subsequent statistical parametric mapping of the main effects of the drug was performed by identifying changes in the BOLD signal. RESULTS Acute reboxetine challenge at a low dose (10 mg/kg i.p.) produced positive BOLD responses specifically in the hypothalamus, whereas a larger dose (30 mg/kg i.p.) produced activations in the hypothalamus, anterior hippocampus and prefrontal cortex. Chronic reboxetine (30 mg/kg i.p.) treatment induced increased BOLD responses in the posterior hippocampus and prefrontal cortex, while no significant contrast changes were observed in the hypothalamus and a significant decrease was apparent in the amygdala. In contrast, acute bupropion (15 and 30 mg/kg i.p.) challenge in both doses produced no significant contrast changes in the regions of interest. However, chronic bupropion treatment (30 mg/kg i.p.) produced robust increases in BOLD responses in the hippocampus, amygdala and prefrontal cortex. CONCLUSION In summary, this study demonstrates that reboxetine and bupropion evoke a significant increase in BOLD functional activity in specific regions of the brain, including the hypothalamus, hippocampus, prefrontal cortex and amygdala. Furthermore, the study illustrates the potential value of pharmacological MRI in rodents to delineate pharmacologically induced changes in regional brain function.
Collapse
Affiliation(s)
- Sakthivel Sekar
- Psychobiology Research Group, Institute of Neuroscience, Newcastle University, Newcastle, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. PLoS One 2011; 6:e24126. [PMID: 21931653 PMCID: PMC3169575 DOI: 10.1371/journal.pone.0024126] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Accepted: 08/04/2011] [Indexed: 11/21/2022] Open
Abstract
Rising life expectancies coupled with an increasing awareness of age-related cognitive decline have led to the unwarranted use of psychopharmaceuticals, including acetylcholinesterase inhibitors (AChEIs), by significant numbers of healthy older individuals. This trend has developed despite very limited data regarding the effectiveness of such drugs on non-clinical groups and recent work indicates that AChEIs can have negative cognitive effects in healthy populations. For the first time, we use a combination of EEG and simultaneous EEG/fMRI to examine the effects of a commonly prescribed AChEI (donepezil) on cognition in healthy older participants. The short- and long-term impact of donepezil was assessed using two double-blind, placebo-controlled trials. In both cases, we utilised cognitive (paired associates learning (CPAL)) and electrophysiological measures (resting EEG power) that have demonstrated high-sensitivity to age-related cognitive decline. Experiment 1 tested the effects of 5 mg/per day dosage on cognitive and EEG markers at 6-hour, 2-week and 4-week follow-ups. In experiment 2, the same markers were further scrutinised using simultaneous EEG/fMRI after a single 5 mg dose. Experiment 1 found significant negative effects of donepezil on CPAL and resting Alpha and Beta band power. Experiment 2 replicated these results and found additional drug-related increases in the Delta band. EEG/fMRI analyses revealed that these oscillatory differences were associated with activity differences in the left hippocampus (Delta), right frontal-parietal network (Alpha), and default-mode network (Beta). We demonstrate the utility of simple cognitive and EEG measures in evaluating drug responses after acute and chronic donepezil administration. The presentation of previously established markers of age-related cognitive decline indicates that AChEIs can impair cognitive function in healthy older individuals. To our knowledge this is the first study to identify the precise neuroanatomical origins of EEG drug markers using simultaneous EEG/fMRI. The results of this study may be useful for evaluating novel drugs for cognitive enhancement.
Collapse
|
72
|
Abstract
Investigating pharmacological modulation of brain activity using magnetic resonance imaging (MRI) presents an exciting opportunity to bridge the gap between preclinical and clinical studies, and holds the potential to be a useful tool in the discovery and development of novel therapeutic agents. Most functional MRI studies to date have utilized the blood oxygen level dependent (BOLD) contrast mechanism. Although this has some advantages over other techniques and is widely available, BOLD has two significant limitations for the study of drug effects; it is an indirect measurement of neuronal function, and produces only a relative (non-quantitative) measure of blood dynamics. Here we describe the various experimental manipulations that have been used to reduce the impact of these limitations, and discuss new ways of collecting and analysing imaging data that allow us to assess functional connectivity of the brain. We recommend some complementary techniques (such as arterial spin labelling and magnetoencephalography) that, if used in conjunction with BOLD functional MRI, will increase the interpretability and thus the utility of MRI for pharmacology research.
Collapse
Affiliation(s)
- Susannah E Murphy
- Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX.
| | | |
Collapse
|
73
|
Haley GE, Kroenke C, Schwartz D, Kohama SG, Urbanski HF, Raber J. Hippocampal M1 receptor function associated with spatial learning and memory in aged female rhesus macaques. AGE (DORDRECHT, NETHERLANDS) 2011; 33:309-320. [PMID: 20890730 PMCID: PMC3168603 DOI: 10.1007/s11357-010-9184-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2010] [Accepted: 09/03/2010] [Indexed: 05/29/2023]
Abstract
Of the acetylcholine muscarinic receptors, the type 1 (M1) and type 2 (M2) receptors are expressed at the highest levels in the prefrontal cortex (PFC) and hippocampus, brain regions important for cognition. As equivocal findings of age-related changes of M1 and M2 in the nonhuman primate brain have been reported, we first assessed age-related changes in M1 and M2 in the PFC and hippocampus using saturation binding assays. Maximum M1 receptor binding, but not affinity of M1 receptor binding, decreased with age. In contrast, the affinity of M2 receptor binding, but not maximum M2 receptor binding, increased with age. To determine if in the elderly cognitive performance is associated with M1 or M2 function, we assessed muscarinic function in elderly female rhesus macaques in vivo using a scopolamine challenge pharmacological magnetic resonance imaging and in vitro using saturation binding assays. Based on their performance in a spatial maze, the animals were classified as good spatial performers (GSP) or poor spatial performers (PSP). In the hippocampus, but not PFC, the GSP group showed a greater change in T(2)*-weighted signal intensity after scopolamine challenge than the PSP group. The maximum M1 receptor binding and receptor binding affinity was greater in the GSP than the PSP group, but no group difference was found in M2 receptor binding. Parameters of circadian activity positively correlated with the difference in T(2)*-weighted signal intensity before and after the challenge, the maximum M1 receptor binding, and the M1 receptor binding affinity. Thus, while in rhesus macaques, there are age-related decreases in M1 and M2 receptor binding, in aged females, hippocampal M1, but not M2, receptor function is associated with spatial learning and memory and circadian activity.
Collapse
Affiliation(s)
- Gwendolen E. Haley
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006 USA
- Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239 USA
| | - Chris Kroenke
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006 USA
- Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239 USA
| | - Daniel Schwartz
- Portland Veterans Administration Medical Center, Division of Psychiatry, Oregon Health and Science University, Portland, OR 97239 USA
| | - Steven G. Kohama
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006 USA
| | - Henryk F. Urbanski
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006 USA
- Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR 97239 USA
- Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239 USA
| | - Jacob Raber
- Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR 97006 USA
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239 USA
- Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239 USA
| |
Collapse
|
74
|
|
75
|
Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements. Drug Discov Today 2011; 16:583-93. [PMID: 21635967 DOI: 10.1016/j.drudis.2011.05.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Revised: 04/19/2011] [Accepted: 05/11/2011] [Indexed: 11/30/2022]
Abstract
There is increasing interest in the application of quantitative magnetic resonance imaging (MRI) methods to drug development, but as yet little standardization or best practice guidelines for its use in this context. Pharmaceutical trials are subject to regulatory constraints and sponsor company processes, including site qualification and expectations around study oversight, blinding, quality assurance and quality control (QA/QC), analysis and reporting of results. In this article, we review the processes on the sponsor side and also the procedures involved in data acquisition at the imaging site. We then propose summary recommendations to help guide appropriate imaging site qualification, as part of a framework of 'good imaging practice' for functional (f)MRI studies applied to drug development.
Collapse
Affiliation(s)
- Adam J Schwarz
- Brain Imaging Center, McLean Hospital, 115 Mill St. Belmont, MA 02478, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices. Drug Discov Today 2011; 16:671-82. [PMID: 21477664 DOI: 10.1016/j.drudis.2011.03.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Revised: 03/09/2011] [Accepted: 03/31/2011] [Indexed: 11/15/2022]
Abstract
Functional magnetic resonance imaging (fMRI) experiments are more complex compared with standard radiological imaging, involving additional data streams and hardware along with complex analysis methods. Here, we propose guidelines based around mitigating risks associated with the complexities of the technique at the level of the individual imaging protocol, including workable and effective quality assurance/quality control procedures and rigorous, predefined, analysis pipelines. Our aim is to provide a framework for 'good imaging practice' (GIP), enabling these requirements to be addressed at an appropriate level of detail. The development of a procedural framework for GIP in pharmaceutical fMRI studies could lead to greater acceptance of the method within industry and facilitate validation and, eventually, qualification of the technique as an imaging biomarker.
Collapse
Affiliation(s)
- Adam J Schwarz
- Imaging Consortium for Drug Development, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
77
|
Obesity as an addiction: Why do the obese eat more? Maturitas 2011; 68:342-5. [DOI: 10.1016/j.maturitas.2011.01.018] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2011] [Accepted: 01/28/2011] [Indexed: 01/11/2023]
|
78
|
Wang DJJ, Chen Y, Fernández-Seara MA, Detre JA. Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2011; 337:359-66. [PMID: 21317356 DOI: 10.1124/jpet.110.172577] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Pharmacological magnetic resonance imaging (phMRI) is increasingly being used in drug discovery and development to speed the translation from the laboratory to the clinic. The two primary methods in phMRI include blood-oxygen-level-dependent (BOLD) contrast and arterial spin-labeled (ASL) perfusion MRI. BOLD contrast has been widely applied in existing phMRI studies. However, because of the lack of absolute quantification and poor reproducibility over time scales longer than hours or across scanning sessions, BOLD fMRI may not be suitable to track oral and other long-term drug effects on baseline brain function. As an alternative method, ASL provides noninvasive, absolute quantification of cerebral blood flow both at rest and during task activation. ASL perfusion measurements have been shown to be highly reproducible over minutes and hours to days and weeks. These two characteristics make ASL an ideal tool for phMRI for studying both intravenous and oral drug action as well as understanding drug effects on baseline brain function and brain activation to cognitive or sensory processing. When ASL is combined with BOLD fMRI, drug-induced changes in cerebral metabolic rate of oxygen may also be inferred. Representative phMRI studies using ASL perfusion MRI on caffeine, remifentanil, and metoclopramide (dopamine antagonist) are reviewed here, with an emphasis on the methodologies used to control for potentially confounding vascular and systemic effects. Both the potentials and limitations of using ASL as an imaging marker of drug action are discussed.
Collapse
Affiliation(s)
- Danny J J Wang
- Ahmanson-Lovelace Brain Mapping Center, University of California Department of Neurology, 660 Charles E Young Dr South, Los Angeles, CA 90095, USA.
| | | | | | | |
Collapse
|
79
|
Holschneider DP, Bradesi S, Mayer EA. The role of experimental models in developing new treatments for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2011; 5:43-57. [PMID: 21309671 PMCID: PMC3124306 DOI: 10.1586/egh.10.88] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Irritable bowel syndrome (IBS) is characterized by chronic, recurrent abdominal pain and altered bowel habits and is currently defined by symptom criteria and the absence of detectable organic disease. The underlying pathophysiology remains incompletely understood. Despite considerable efforts by the scientific community and the pharmaceutical industry to develop novel pharmacological treatments aimed at chronic visceral pain, the traditional approach to identifying and evaluating novel drugs for this target have largely failed to translate into effective IBS treatments. However, several novel drugs aimed at normalizing bowel movements have produced clinical effects, not only on the primary target, but also on pain and discomfort. While some of the commonly used experimental animal models for the pain dimension of IBS have some face and construct validity, the predictive validity of most of the models is either unknown, or has been disappointing. A reverse translational approach is proposed, which is based on identification and characterization of brain endophenotypes in patients, followed by translation of these endophenotypes for pharmacological studies in rodent models.
Collapse
Affiliation(s)
- Daniel P Holschneider
- VA Greater Los Angeles Healthcare System, LA, CA, USA,Departments of Psychiatry and the Behavioral Sciences, Neurology, Cell & Neurobiology, Biomedical Engineering, University of Southern California, Los Angeles, CA, USA
| | - Sylvie Bradesi
- VA Greater Los Angeles Healthcare System, LA, CA, USA,UCLA Center for Neurobiology of Stress, Departments of Medicine, Physiology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA,Author for correspondence:
| | - Emeran A Mayer
- VA Greater Los Angeles Healthcare System, LA, CA, USA,UCLA Center for Neurobiology of Stress, Departments of Medicine, Physiology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
| |
Collapse
|
80
|
Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 2011; 30:16284-92. [PMID: 21123574 DOI: 10.1523/jneurosci.2590-10.2010] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Adenosine A(2a) receptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models. Rodent studies support the hypothesis that A(2a) antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway. One way to test this hypothesis in humans is to quantify regional pharmacodynamic responses with cerebral blood flow (CBF) imaging. That approach has also been proposed as a tool to accelerate pharmaceutical dose finding, but has not yet been applied in humans to drugs in development. We successfully addressed both these aims with a perfusion magnetic resonance imaging (MRI) study of the novel adenosine A(2a) antagonist SYN115. During a randomized, double-blind, placebo-controlled, crossover study in 21 PD patients on levodopa but no agonists, we acquired pulsed arterial spin labeling MRI at the end of each treatment period. SYN115 produced a highly significant decrease in thalamic CBF, consistent with reduced pallidothalamic inhibition via the indirect pathway. Similar decreases occurred in cortical regions whose activity decreases with increased alertness and externally focused attention, consistent with decreased self-reported sleepiness on SYN115. Remarkably, we also derived quantitative pharmacodynamic parameters from the CBF responses to SYN115. These results suggested that the doses tested were on the low end of the effective dose range, consistent with clinical data reported separately. We conclude that (1) SYN115 enters the brain and exerts dose-dependent regional effects, (2) the most prominent of these effects is consistent with deactivation of the indirect pathway as predicted by preclinical studies; and (3) perfusion MRI can provide rapid, quantitative, clinically relevant dose-finding information for pharmaceutical development.
Collapse
|
81
|
Borsook D, Sava S, Becerra L. The pain imaging revolution: advancing pain into the 21st century. Neuroscientist 2010; 16:171-85. [PMID: 20400714 DOI: 10.1177/1073858409349902] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The great advances in brain imaging techniques over the last few decades have determined a shift in our understanding of chronic pain conditions and opened the door for new opportunities to develop better diagnoses and perhaps better drug treatments. Neuroimaging has helped shape the concept of chronic pain from a disease affecting mainly the somatosensory system, to a condition in which emotional, cognitive, and modulatory areas of the brain are affected, in addition to degenerative processes. All these contribute to the development and maintenance of pain symptoms and comorbid features, including alterations in anxiety, depression, and cognitive processes. In this article the authors review the current understanding of the brain changes in chronic pain and the developments made possible by the use of various brain imaging techniques. They also discuss the possible applications of brain imaging to developing a "pain phenotype" that could aid in diagnostic and treatment choices of chronic pain conditions.
Collapse
Affiliation(s)
- David Borsook
- Department of Radiology, Children's Hospital Boston, Waltham, MA 02453, USA
| | | | | |
Collapse
|
82
|
CNS animal fMRI in pain and analgesia. Neurosci Biobehav Rev 2010; 35:1125-43. [PMID: 21126534 DOI: 10.1016/j.neubiorev.2010.11.005] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 11/22/2010] [Accepted: 11/23/2010] [Indexed: 11/22/2022]
Abstract
Animal imaging of brain systems offers exciting opportunities to better understand the neurobiology of pain and analgesia. Overall functional studies have lagged behind human studies as a result of technical issues including the use of anesthesia. Now that many of these issues have been overcome including the possibility of imaging awake animals, there are new opportunities to study whole brain systems neurobiology of acute and chronic pain as well as analgesic effects on brain systems de novo (using pharmacological MRI) or testing in animal models of pain. Understanding brain networks in these areas may provide new insights into translational science, and use neural networks as a "language of translation" between preclinical to clinical models. In this review we evaluate the role of functional and anatomical imaging in furthering our understanding in pain and analgesia.
Collapse
|
83
|
Abstract
The integration of functional magnetic resonance imaging (fMRI) with cognitive and affective neuroscience paradigms enables examination of the brain systems underlying the behavioral deficits manifested in schizophrenia; there have been a remarkable increase in the number of studies that apply fMRI in neurobiological studies of this disease. This article summarizes features of fMRI methodology and highlights its application in neurobehavioral studies in schizophrenia. Such work has helped elucidate potential neural substrates of deficits in cognition and affect by providing measures of activation to neurobehavioral probes and connectivity among brain regions. Studies have demonstrated abnormalities at early stages of sensory processing that may influence downstream abnormalities in more complex evaluative processing. The methodology can help bridge integration with neuropharmacologic and genomic investigations.
Collapse
Affiliation(s)
- Raquel E Gur
- Department of Psychiatry, Neuropsychiatry Section, University of Pennsylvania Medical Center, 10th Floor, Gates Building, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
84
|
Murnane KS, Howell LL. Development of an apparatus and methodology for conducting functional magnetic resonance imaging (fMRI) with pharmacological stimuli in conscious rhesus monkeys. J Neurosci Methods 2010; 191:11-20. [PMID: 20566353 PMCID: PMC2915932 DOI: 10.1016/j.jneumeth.2010.06.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Revised: 04/28/2010] [Accepted: 06/01/2010] [Indexed: 11/23/2022]
Abstract
Functional magnetic resonance imaging (fMRI) is a technique with significant potential to advance our understanding of multiple brain systems. However, when human subjects undergo fMRI studies they are typically conscious whereas pre-clinical fMRI studies typically utilize anesthesia, which complicates comparisons across studies. Therefore, we have developed an apparatus suitable for imaging conscious rhesus monkeys. In order to minimize subject stress and spatial motion, each subject was acclimated to the necessary procedures over several months. The effectiveness of this process was then evaluated, in fully trained subjects, by quantifying objective physiological measures. These physiological metrics were stable both within and across sessions and did not differ from when these same subjects were immobilized using standard primate handling procedures. Subject motion and blood oxygenation level dependent (BOLD) fMRI measurements were then evaluated by scanning subjects under three different conditions: the absence of stimulation, presentation of a visual stimulus, or administration of intravenous (i.v.) cocaine (0.3mg/kg). Spatial motion differed neither by condition nor along the three principal axes. In addition, maximum translational and rotational motion never exceeded one half of the voxel size (0.75 mm) or 1.5 degrees, respectively. Furthermore, the localization of changes in blood oxygenation closely matched those reported in previous studies using similar stimuli. These findings document the feasibility of fMRI data collection in conscious rhesus monkeys using these procedures and allow for the further study of the neural effects of psychoactive drugs.
Collapse
Affiliation(s)
- Kevin Sean Murnane
- Division of Neuroscience, Yerkes National Primate Research Center, Atlanta, GA USA
| | - Leonard Lee Howell
- Division of Neuroscience, Yerkes National Primate Research Center, Atlanta, GA USA
- Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA
| |
Collapse
|
85
|
Larsson PG, Eeg-Olofsson O, Michel CM, Seeck M, Lantz G. Decrease in propagation of interictal epileptiform activity after introduction of levetiracetam visualized with electric source imaging. Brain Topogr 2010; 23:269-78. [PMID: 20574764 DOI: 10.1007/s10548-010-0150-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Accepted: 05/29/2010] [Indexed: 11/29/2022]
Abstract
Different neuroimaging techniques (fMRI, spectroscopy, PET) are being used to evaluate candidate drugs in pharmacological development. In patients with epilepsy fast propagation of the epileptiform activity between different brain areas occurs. Electric Source Imaging (ESI), in contrast to the aforementioned techniques, has a millisecond time resolution, allowing visualization of this fast propagation. The purpose of the current project was to use ESI to investigate whether introduction of an antiepileptic drug (levetiracetam, LEV) would change the propagation patterns of the interictal epileptiform activity. Thirty patients with epilepsy were subject to an EEG recording before (pre-LEV) and after (in-LEV) introduction of LEV. Interictal spikes with similar topographic distribution were averaged within each subject, and a distributed source model was used to localize the EEG sources of the epileptiform activity. The temporal development of the activity within 20 regions of interest (ROIs) was determined, and source propagation between different regions was compared between the pre-LEV and in-LEV recordings. Patients with epileptic seizures showed propagation in 22/24 identified spike types in the pre-LEV recordings. In the in-LEV recordings only 7/15 spike types showed propagation, and six of these seven propagating spikes were recorded in patients with poor effect of treatment. Also in patients without seizures LEV tended to suppress propagation. We conclude that the observed suppression of source propagation can be considered as an indicator of effective antiepileptic treatment. ESI might thus become a useful tool in the early clinical evaluation of new candidate drugs in pharmacological development.
Collapse
Affiliation(s)
- Pål G Larsson
- Department of Neurosurgery, Oslo University Hospital, Oslo, 0027, Norway
| | | | | | | | | |
Collapse
|
86
|
Jacobs GE, der Grond JV, Teeuwisse WM, Langeveld TJC, van Pelt J, Verhagen JCM, de Kam ML, Cohen AF, Zitman FG, van Gerven JMA. Hypothalamic glutamate levels following serotonergic stimulation: a pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:486-91. [PMID: 20138102 DOI: 10.1016/j.pnpbp.2010.01.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2009] [Revised: 01/10/2010] [Accepted: 01/27/2010] [Indexed: 01/10/2023]
Abstract
INTRODUCTION AND PURPOSE Functional proton magnetic resonance spectroscopy (MRS) can be applied to measure pharmacodynamic effects of central nervous system (CNS)-active drugs. The serotonin precursor 5-hydroxytryptophan (5-HTP), administered together with carbidopa and granisetron to improve kinetics and reduce adverse effects, acutely enhances central serotonergic neurotransmission and induces hypothalamus-pituitary-adrenal-(HPA) axis activation. We studied the hypothalamic levels of glutamate/glutamine (Glx), choline (Chol), N-acetyl-aspartate (NAA) and creatine using 7-Tesla (7T) MRS, and adrenocorticotropic hormone (ACTH) and cortisol in peripheral blood, after the administration of the 5-HTP function test in healthy volunteers. METHODS A randomized, double blind, placebo-controlled, two-way cross-over study was performed in 12 healthy males with a 7day wash-out period. After administration of the oral 5-HTP function test, ACTH and cortisol were measured over 4h and MRS scans at 7T were performed every 30min over 3h measuring Glx:Creatine, Chol:Creatine and NAA:Creatine ratios. RESULTS In the hypothalamus, the administration of 5-HTP had no effect on the average Glx, Chol or NAA levels over 180min but induced a significant decrease of Glx at 60min on post-hoc analysis. 5-HTP-induced significant ACTH release reaching an E(max) of 60.2ng/L at 80min followed by cortisol with an E(max) of 246.4ng/mL at 110min. CONCLUSIONS The reduction in hypothalamic Glx levels after serotonergic stimulation is compatible with activation of excitatory neurons in this region, which is expected to cause depletion of local glutamate stores. The hypothalamic MRS-response reached its maximum prior to subsequent increases of ACTH and cortisol, which support the functional relevance of hypothalamic Glx-depletion for activation of the HPA-axis. This exploratory study shows that MRS is capable of detecting neuronal activation following functional stimulation of a targeted brain area.
Collapse
Affiliation(s)
- G E Jacobs
- Centre for Human Drug Research, Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Abstract
Pain is a complex subjective phenomenon that so far cannot be objectively quantified by any standardized procedure. This fact renders it also difficult to measure the efficacy of analgesic drugs. In recent years the application of functional magnetic resonance imaging (fMRI) has significantly increased our current knowledge about the brain physiological correlates of pain in humans. The technique is non-invasive and detects the increased blood flow into neuronally active brain regions based on the so-called BOLD (blood oxygenation level dependent) effect of T2-weighted MRI. This paper gives an overview of the application of pharmacological fMRI (phfMRI) as an approach to evaluate the efficacy of analgesics. In contrast to EEG- and MEG-based methods phfMRI allows more flexibility in the design of experimental paradigms and stimulus protocols to account for the diversity of clinical pain types (inflammatory pain, tactile allodynia etc.) or their dependence upon psychological circumstances (anxiety, depression, stress) in which pain occurs. However, in order to specifically refer results from phfMRI to the neuronal processes underlying pain, future research needs to increase the understanding of the mechanisms underlying the neurovascular coupling reaction represented by the BOLD technique. The same applies for the influence of cerebrovascular diseases on the BOLD response.
Collapse
|
88
|
Interleaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid have different effects on corticolimbic activity. Psychopharmacology (Berl) 2010; 209:233-44. [PMID: 20195575 DOI: 10.1007/s00213-010-1786-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Accepted: 01/24/2010] [Indexed: 02/07/2023]
Abstract
RATIONALE Combined transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI) can be used to study anticonvulsant drugs. A previous study showed that lamotrigine (LTG) inhibited brain activation induced when TMS was applied over motor cortex, whereas it increased activation induced by TMS applied over prefrontal cortex. OBJECTIVES The present double-blind, placebo-controlled, crossover study in 30 healthy subjects again combined TMS and fMRI to test whether the effects seen previously with LTG would be confirmed and to compare these with a second anticonvulsant drug, valproic acid (VPA). RESULTS Statistical parametric mapping analysis showed that both LTG and VPA, compared to placebo, inhibited TMS-induced activation of the motor cortex. In contrast, when TMS was applied over prefrontal cortex, LTG increased the activation of limbic regions, confirming previous results; VPA had no effect. CONCLUSION We conclude that LTG and VPA have similar inhibitory effects on motor circuits, but differing effects on the prefrontal corticolimbic system. The study demonstrates that a combination of TMS and fMRI techniques may be useful in the study of the effects of neuroactive drugs on specific brain circuits.
Collapse
|
89
|
Tracey I, Bushnell MC. How neuroimaging studies have challenged us to rethink: is chronic pain a disease? THE JOURNAL OF PAIN 2010; 10:1113-20. [PMID: 19878862 DOI: 10.1016/j.jpain.2009.09.001] [Citation(s) in RCA: 252] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2009] [Revised: 07/19/2009] [Indexed: 01/20/2023]
Abstract
UNLABELLED In this review, we present data from functional, structural, and molecular imaging studies in patients and animals supporting the notion that it might be time to reconsider chronic pain as a disease. Across a range of chronic pain conditions, similar observations have been made regarding changes in structure and function within the brains of patients. We discuss these observations within the framework of the current definition of a disease. PERSPECTIVE Neuroimaging studies have made a significant scientific impact in the study of pain. Knowledge of nociceptive processing in the noninjured and injured central nervous system has grown considerably over the past 2 decades. This review examines the information from these functional, structural, and molecular studies within the framework of a disease state.
Collapse
Affiliation(s)
- Irene Tracey
- Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, Nuffield Department of Anaesthetics, University of Oxford, John Radcliffe Hospital, Headington, England, UK.
| | | |
Collapse
|
90
|
Williams JM, Milatovic D, Gore JC, Aschner M, Avison MJ. Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study. Toxicol Sci 2010; 114:310-22. [PMID: 20061340 DOI: 10.1093/toxsci/kfq002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The parkinsonian symptoms and increased Mn accumulation in dopaminergic (DAergic) neurons of the basal ganglia implicate impaired dopamine signaling in the neurotoxic effects of chronic manganese overexposure. Using blood oxygenation level-dependent (BOLD) pharmacological magnetic resonance imaging (phMRI), we mapped brain responses to acute amphetamine (AMPH; 3 mg/kg, ip), which stimulates midbrain DAergic systems, in male Sprague-Dawley rats following 6 weeks of chronic MnCl(2) (5 mg Mn/kg, one per week, iv) or saline treatment. Plasma Mn content, measured immediately following phMRI, was elevated twofold in Mn-treated animals (p < 0.05), but the twofold increase in mean striatal Mn content did not reach significance. In saline-treated animals, AMPH stimulated robust positive BOLD responses throughout the basal ganglia and their reciprocally innervated connections. In contrast, acute AMPH stimulated a negative BOLD response in many of these structures in the Mn-treated group, resulting in significant differences between saline- and Mn-treated AMPH-evoked BOLD responses within caudate putamen, globus pallidus, substantia nigra, mediodorsal thalamic nucleus, and somatosensory cortex. These results demonstrate the utility of AMPH-evoked phMRI as readout of the DAergic signaling in vivo and confirm the vulnerability of DAergic systems to Mn.
Collapse
Affiliation(s)
- Jason M Williams
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
| | | | | | | | | |
Collapse
|
91
|
Moeller FG, Kjome KL, Ma L. Imaging advances in developing new medications for addiction. Neuropsychopharmacology 2010; 35:339-40. [PMID: 20010706 PMCID: PMC3055425 DOI: 10.1038/npp.2009.98] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Frederick Gerard Moeller
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
| | - Kimberly L Kjome
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Liangsuo Ma
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA
| |
Collapse
|
92
|
Microneurography: an opportunity for translational drug development in neuropathic pain. Neurosci Lett 2009; 470:155-7. [PMID: 20045040 DOI: 10.1016/j.neulet.2009.12.065] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
93
|
Mueggler T, Baltes C, Rudin M. Molecular neuroimaging in rodents: assessing receptor expression and function. Eur J Neurosci 2009; 30:1860-9. [DOI: 10.1111/j.1460-9568.2009.06987.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
94
|
Abstract
Neuroimaging makes it possible to study pain processing beyond the peripheral nervous system, at the supraspinal level, in a safe, noninvasive way, without interfering with neurophysiological processes. In recent years, studies using brain imaging methods have contributed to our understanding of the mechanisms responsible for the development and maintenance of chronic pain. Moreover, neuroimaging shows promising results for analgesic drug development and in characterizing different types of pain, bringing us closer to development of mechanism-based diagnoses and treatments for the chronic pain patient.
Collapse
Affiliation(s)
- Karolina Wartolowska
- grid.4991.50000000419368948Centre for Functional Magnetic Resonance Imaging of the Brain, Department of Clinical Neurology, and Nuffield Department of Anaesthetics, University of Oxford, Oxford, England, OX3 9DU, UK
| | - Irene Tracey
- grid.4991.50000000419368948Centre for Functional Magnetic Resonance Imaging of the Brain, Department of Clinical Neurology, and Nuffield Department of Anaesthetics, University of Oxford, Oxford, England, OX3 9DU, UK
| |
Collapse
|
95
|
Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol 2009; 12:1009-20. [PMID: 19545475 PMCID: PMC2846821 DOI: 10.1017/s1461145709990149] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The anterior cingulate cortex (ACC) and insula are important neural substrates for the integration of cognitive, emotional, and physiological information, as well as the coordination of responses to anticipated stimuli. Increased neural activation within these structures has been observed in individuals with anxiety and depressive disorders. Selective serotonin reuptake inhibitors (SSRIs) are among the most effective and frequently prescribed anxiolytic agents, yet it is not known whether ACC or insula underlie the effects of these drugs. We examined whether subchronic administration of a SSRI to healthy volunteers attenuates activation in ACC or insula during anticipation, an important emotional process underlying anxiety. Support for this hypothesis would help to understand where and by what process SSRIs may exert beneficial effects as anxiolytics and would provide further mechanistic evidence for functional magnetic resonance imaging (fMRI) as a biomarker for the development of anxiolytics. Fifteen volunteers participated in a double-blind, placebo-controlled, randomized cross-over study. Participants completed a pleasant and aversive picture-cued anticipation task during fMRI after taking either escitalopram (10 mg) or placebo for 21 d. We found that escitalopram significantly decreased activation in bilateral posterior and middle insula during the anticipation condition irrespective of stimulus valence and in medial prefrontal and ACC during anticipation of aversive vs. pleasant images. Reduced insular and ACC activation in healthy controls during anticipation may be integral to the therapeutic efficacy of SSRIs and may provide a mechanistic approach for the use of pharmaco-fMRI in the identification of novel pharmacotherapeutic agents in patient populations.
Collapse
|
96
|
fMRI investigation of the effect of local and systemic lidocaine on noxious electrical stimulation-induced activation in spinal cord. Pain 2009; 145:110-9. [DOI: 10.1016/j.pain.2009.05.026] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2008] [Revised: 04/10/2009] [Accepted: 05/27/2009] [Indexed: 11/19/2022]
|
97
|
On-line plasticity in spoken sentence comprehension: Adapting to time-compressed speech. Neuroimage 2009; 49:1124-32. [PMID: 19632341 PMCID: PMC2775905 DOI: 10.1016/j.neuroimage.2009.07.032] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2009] [Revised: 07/02/2009] [Accepted: 07/15/2009] [Indexed: 11/24/2022] Open
Abstract
Listeners show remarkable flexibility in processing variation in speech signal. One striking example is the ease with which they adapt to novel speech distortions such as listening to someone with a foreign accent. Behavioural studies suggest that significant improvements in comprehension occur rapidly — often within 10–20 sentences. In the present experiment, we investigate the neural changes underlying on-line adaptation to distorted speech using time-compressed speech. Listeners performed a sentence verification task on normal-speed and time-compressed sentences while their neural responses were recorded using fMRI. The results showed that rapid learning of the time-compressed speech occurred during presentation of the first block of 16 sentences and was associated with increased activation in left and right auditory association cortices and in left ventral premotor cortex. These findings suggest that the ability to adapt to a distorted speech signal may, in part, rely on mapping novel acoustic patterns onto existing articulatory motor plans, consistent with the idea that speech perception involves integrating multi-modal information including auditory and motoric cues.
Collapse
|
98
|
Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009; 194:535-40. [PMID: 19478294 PMCID: PMC2802527 DOI: 10.1192/bjp.bp.108.056093] [Citation(s) in RCA: 180] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Selective serotonin reuptake inhibitors (SSRIs) are typically thought to have a delay of several weeks in the onset of their clinical effects. However, recent reports suggest they may have a much earlier therapeutic onset. A reduction in amygdala responsivity has been implicated in the therapeutic action of SSRIs. AIMS To investigate the effect of a single dose of an SSRI on the amygdala response to emotional faces. METHOD Twenty-six healthy volunteers were randomised to receive a single oral dose of citalopram (20 mg) or placebo. Effects on the processing of facial expressions were assessed 3 h later using functional magnetic resonance imaging. RESULTS Volunteers treated with citalopram displayed a significantly reduced amygdala response to fearful facial expressions compared with placebo. CONCLUSIONS Such an immediate effect of an SSRI on amygdala responses to threat supports the idea that antidepressants have an earlier onset of therapeutically relevant effects than conventionally thought.
Collapse
|
99
|
Bruns A, Künnecke B, Risterucci C, Moreau JL, von Kienlin M. Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med 2009; 61:1451-8. [DOI: 10.1002/mrm.21779] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
100
|
Effects of acute nicotine on brain function in healthy smokers and non-smokers: Estimation of inter-individual response heterogeneity. Neuroimage 2009; 45:549-61. [DOI: 10.1016/j.neuroimage.2008.12.029] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Revised: 11/09/2008] [Accepted: 12/15/2008] [Indexed: 11/19/2022] Open
|